Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H1 2020, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.
Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 3, 4, 1, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase 0, Preclinical and Discovery stages comprises 1, 2, 1, 2 and 1 molecules, respectively.
Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neisseria meningitidis Infections - Overview
Neisseria meningitidis Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neisseria meningitidis Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Bioworld Technologies Sdn Bhd
CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Hilleman Laboratories Pvt Ltd
ImmunoBiology Ltd
Johnson & Johnson
Neoculi Pty Ltd
Novo Medi Sciences Pvt Ltd
Omvax Inc
Pfizer Inc
ReAlta Life Sciences Inc
Sanofi Pasteur SA
Serum Institute of India Ltd
Wellstat Vaccines LLC
Neisseria meningitidis Infections - Drug Profiles
(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACYW-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MenBioVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, B, C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C] (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes C, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [strain C2135] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCL-195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neisseria meningitidis [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06886992 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RLS-0071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neisseria meningitidis Infections - Dormant Projects
Neisseria meningitidis Infections - Discontinued Products
Neisseria meningitidis Infections - Product Development Milestones
Featured News & Press Releases
Aug 29, 2019: $440 million funding boost for vital health and medical research for all stages of life
Nov 28, 2018: NIHR supports world-first trial of new nose drop to fight meningitis
Jun 27, 2018: European approval for lower dose of GSk's Meningitis vaccine
Jun 18, 2018: New way to determine protection of Men B vaccine against different strains
Apr 23, 2018: Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
Mar 06, 2018: TRUMENBA (Meningococcal Group B Vaccine) Now Available In Canada
Feb 07, 2018: GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
Dec 13, 2017: Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Data Published In New England Journal Of Medicine Demonstrate The Vaccine’s Immunogenicity
Nov 22, 2017: Meningococcal Vaccine Antigens expressed by 91 Percent of Tested Bacterial Strains
Sep 12, 2017: TGA approves MENVEO vaccine to help protect babies from two months old from meningococcal disease
Jul 11, 2017: Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection
May 30, 2017: European Commission Approves Pfizer's Trumenba To Help Prevent Meningococcal Group B Disease In Adolescents And Adults
May 15, 2017: GlaxoSmithKline Announces (meningococcal B) vaccine availability
Mar 24, 2017: Pfizer Receives Positive CHMP Opinion for TRUMENBA for Prevention of Meningococcal Group B Disease
Mar 24, 2017: GSK Announces Availability of Menveo (meningococcal ACWY vaccine)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Neisseria meningitidis Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
Neisseria meningitidis Infections - Pipeline by Bioworld Technologies Sdn Bhd, H1 2020
Neisseria meningitidis Infections - Pipeline by CanSino Biologics Inc, H1 2020
Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
Neisseria meningitidis Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H1 2020
Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, H1 2020
Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, H1 2020
Neisseria meningitidis Infections - Pipeline by Neoculi Pty Ltd, H1 2020
Neisseria meningitidis Infections - Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020
Neisseria meningitidis Infections - Pipeline by Omvax Inc, H1 2020
Neisseria meningitidis Infections - Pipeline by Pfizer Inc, H1 2020
Neisseria meningitidis Infections - Pipeline by ReAlta Life Sciences Inc, H1 2020
Neisseria meningitidis Infections - Pipeline by Sanofi Pasteur SA, H1 2020
Neisseria meningitidis Infections - Pipeline by Serum Institute of India Ltd, H1 2020
Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, H1 2020
Neisseria meningitidis Infections - Dormant Projects, H1 2020
Neisseria meningitidis Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
Neisseria meningitidis Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
Neisseria meningitidis Infections - Discontinued Products, H1 2020
List of Figures
Number of Products under Development for Neisseria meningitidis Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
